Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department

• Sponsor: Antonios Likourezos (Other)
• Overall Status: Completed
• CT.gov ID: NCT01835262
• Collaborator: (none)
• Enrollment: 90
• Location: 1
• Arms: 2
• Duration (Months): 13
• Patients Per Site Per Month: 6.9

Study Details

Study Description

Brief Summary

The primary objectives of the study are to evaluate the efficacy of subdissociative dose intravenous ketamine compared with intravenous morphine in relieving acute pain in the ED. Secondary objectives will include the rate of adverse effects and need for rescue analgesia. The hypothesis is that intravenous administration of subdissociative dose ketamine at 0.3 mg/kg is superior to intravenous morphine at 0.1mg/kg in treating moderate and severe acute pain in patients presenting to the ED.

Condition or Disease	Intervention/Treatment	Phase
Pain	Drug: Morphine; Drug: Ketamine	Phase 4

Detailed Description

Rationale: Opioids are traditionally accepted as a cornerstone of acute pain management in the Emergency Department (ED). Morphine is one of the most commonly used parenteral opioid analgesics whose initial dose of 0.1 mg/kg has been extensively researched and recommended for control of severe acute pain in the ED. However, intravenous administration of opioids is associated with thefollowing side effects: hypotension, respiratory depression, dizziness, pruritis and nausea. In addition, in patients with pre-existing renal and/or hepatic insufficiency, these effects may be pronounced and require interventions. Thus, the administration of an equipotent analgesic that does not cause hypotension and respiratory depression would enhance patient safety in the ED.

Ketamine is a noncompetitive N-methyl D-aspartate (NMDA) receptor antagonist that blocks the release of excitatory neurotransmitter glutamate and provides anesthesia, amnesia and analgesia by virtue of decreasing central sensitization and "wind-up" phenomenon. Due to its high lipid solubility, ketamine rapidly crosses the blood-brain barrier, provides rapid onset of action (peak concentration at is reached 1 minute after IVP) and rapid recovery to baseline (duration of action 5-15 minutes after IVP) (1). When given at subdissociative doses of 0.1-0.5 mg/kg, either as an adjunct to opioid analgesic or as a solo agent, ketamine provides good analgesia while preserving airway patency, ventilation, and cardiovascular stability (2). In addition, a small dose of ketamine may increase the analgesic potency of opioids thus decreasing their dosing requirements (3). Based on the aforementioned facts, ketamine offers an attractive option for providing safe and convenient pain control for patients in the ED.

A double-blind trial of 40 adult patients with acute musculoskeletal trauma compared low-dose ketamine administered by subcutaneous infusion (0.1 mg/kg/h) with intermittent intravenous morphine (0.1 mg/kg IV every 4 hours ) and demonstrated better pain relief, less sedation and less nausea and vomiting with ketamine infusion than with intermittent morphine. In addition, none of the patients in the ketamine group required supplementary analgesia (4). A prospective, randomized trial compared two analgesic regimens, morphine with ketamine (K group) or morphine with placebo (P group) for severe acute pain in 73 trauma patients with a visual analog scale (VAS) score of at least 60/100. Morphine was administered at 0.1mg/kg; patients in the K group received 0.2 mg/kg of intravenous ketamine over 10 minutes while patients in the P group received isotonic sodium chloride solution. The results showed comparable change in VAS score at 30 minutes (34 mm (K) vs. 39 mm (P)) but reduced morphine consumption in the ketamine group (0.14 mg/kg (K) vs 0.2 mg/kg (P)) (5).

A chart review analysis of 35 ED patients receiving low dose ketamine at doses 0.1mg-0.6mg/kg in addition to intravenous morphine demonstrated a decrease in pain intensity for 54% of the patients by a documented 3 point pain decrease on a 10-point scale. The ketamine doses ranged from 5 mg to 35 mg with median dose of 10 mg and mean dose of 15.7mg. In addition, only one patient had a brief dysphoric reaction that did not require intervention (6).

Hypothesis: Intravenous administration of subdissociative dose ketamine at 0.3 mg/kg is superior to intravenous morphine at 0.1 mg/kg in treating moderate and severe acute pain in patients presenting to the ED.

Methods: Prospective, randomized, double-blind trial evaluating and comparing analgesic effect of intravenous Ketamine administered in sub-dissociative doses: 0.3 mg/kg given over 10 minutes with intravenous Morphine given at 0.1mg/kg as a single IVP.

Description: Once patient is triaged, an initial pain score will be assessed and patient's stated weight will be recorded in the chart. Patients will then have an initial evaluation by an attending ED physician and once found to be eligible for the study (deemed by treating physician to warrant administration of intravenous analgesia) patient will be randomized to receive either morphine at 0.1 mg /kg given as IVP or ketamine at 0.3 mg/given as IVP. Patients' vital signs will be recorded at triage, at the beginning of the study and at 15, 30, 60, 90, 120 minutes post-administration. Patients will be placed on a monitor and continuous pulse oximetry (oxygen saturation), blood pressure, heart rate and respiratory rate will be recorded. We will compare efficacy as a difference between 2 groups in pain relief from the baseline (at triage) to 30 minutes post-analgesic administration. The primary outcome is the difference between 2 groups in pain relief at 30 minutes. The secondary outcome is side effects. We will compare the safety profile of each analgesic with respect to incidence of hypotension, respiratory depression, nausea and vomiting, pruritis, need for an opioid reversal agent (naloxone), tachycardia, laryngospasm, hypersalivation, dizziness, agitation and need for benzodiazepines (midazolam) administration for symptomatic evidence of emergence reaction. All the data will be entered and analyzed via SPSS. Data analyses will include frequency distributions, and ANOVA to assess a difference in pain scores between the groups at various time points. All patients will be analyzed with an intent to treat analysis. However, a subgroup analysis will be done for any emergence reaction or event which occurs often.

Study Design

• Study Type: Interventional
• Actual Enrollment: 90 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department: A Prospective, Randomized, Double-Blind Study
• Study Start Date: Apr 1, 2013
• Actual Primary Completion Date: May 1, 2014
• Actual Study Completion Date: May 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Morphine Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP	Drug: Morphine; Morphine: 0.1 mg /kg given as IVP
Experimental: Ketamine Group Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP	Drug: Ketamine; Ketamine:0.3 mg/given as IVP

Outcome Measures

Primary Outcome Measures

1. Numeric Rating Scale of Pain [30 minutes]

   We will compare efficacy as a difference between 2 groups in pain score at 30 minutes post-analgesic administration. The primary outcome is the difference between 2 groups in pain score at 30 minutes. Pain will be measured via Numeric rating scale from 0 to 10 with 0 being no pain, 5 being moderate pain, and 10 being severe pain

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 55 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. ED patients18-55 years old presenting with moderate to severe (Numeric Pain Rating Score >5) acute (less than 7 days)

2. abdominal, flank, back or musculoskeletal pain warranting (in the treating physician's judgment) administration of intravenous opioid pain medication.

3. Patients must be awake, alert and oriented to time, place and person,

4. patient must be able to demonstrate understanding of the informed consent.

5. Patient must be able to verbalize how much pain they are having on the 10 point Numeric Rating Pain Scale,

6. Patient mus be able to verbalize the nature of the side effects he may be experiencing from the intravenous analgesia.

Exclusion Criteria:

1. Pregnancy or breast feeding

2. SBP<90

3. Weight greater than 115kg or less than 45kg,

4. altered mental status,

5. allergy to ketamine or morphine,

6. history of acute head or ocular trauma

7. presence of intracranial mass or vascular lesion, presence of psychiatric history

8. diagnosis or treatment (as assessed by electronic chart review).

9. history of seizure or intracranial hypertension

10. history of chronic pain, pain syndrome or fibromyalgia

11. presence of cardiovascular disease except controlled hypertension

12. history of acute head or ocular trauma, drug or alcohol abuse in the preceding 6 months

13. drugs or alcohol abuse in the preceding 6 months

14. SBP>180

15. HR<50

16. HR>150

17. RR<10

18. RR>30

19. administration of opiate pain medication in the past 4 hours prior to assessment (i.e. home, EMS, triage, office, etc.)

20. presence of renal or hepatic insufficiency (as assessed by electronic chart review),

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Maimonides Medical Center	Brooklyn	New York	United States	11219

Sponsors and Collaborators

• Antonios Likourezos

Investigators

• Principal Investigator: Sergey Motov, MD, Maimonides Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

• Galinski M, Dolveck F, Combes X, Limoges V, Smaïl N, Pommier V, Templier F, Catineau J, Lapostolle F, Adnet F. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-90.
• Gurnani A, Sharma PK, Rautela RS, Bhattacharya A. Analgesia for acute musculoskeletal trauma: low-dose subcutaneous infusion of ketamine. Anaesth Intensive Care. 1996 Feb;24(1):32-6.
• Javery KB, Ussery TW, Steger HG, Colclough GW. Comparison of morphine and morphine with ketamine for postoperative analgesia. Can J Anaesth. 1996 Mar;43(3):212-5.
• Lester L, Braude DA, Niles C, Crandall CS. Low-dose ketamine for analgesia in the ED: a retrospective case series. Am J Emerg Med. 2010 Sep;28(7):820-7. doi: 10.1016/j.ajem.2009.07.023. Epub 2010 Apr 2.
• Winterfield RW, Fadly AM, Hoerr FJ. Vaccination and revaccination with a Holland (H) strain of infectious bronchitis virus. Avian Dis. 1976 Apr-Jun;20(2):369-74.

• Responsible Party: Antonios Likourezos, Research Manager, Maimonides Medical Center
• ClinicalTrials.gov Identifier: NCT01835262
• Other Study ID Numbers: 12/09/VA01; 12-09-VA01
• First Posted: Apr 18, 2013
• Last Update Posted: Feb 29, 2016
• Last Verified: Oct 1, 2015

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Keywords provided by Antonios Likourezos, Research Manager, Maimonides Medical Center: pain; Ketamine; Emergency Medicine; morphine
• Additional relevant MeSH terms: Emergencies; Ketamine; Morphine

Study Results

Participant Flow

Arm/Group Title	Morphine	Ketamine Group
Arm/Group Description	Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP Morphine: Morphine: 0.1 mg /kg given as IVP	Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP Ketamine: Ketamine:0.3 mg/given as IVP
Period Title: Overall Study
STARTED	45	45
COMPLETED	45	45
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	Morphine	Ketamine Group	Total
Arm/Group Description	Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP Morphine: Morphine: 0.1 mg /kg given as IVP	Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP Ketamine: Ketamine:0.3 mg/given as IVP	Total of all reporting groups
Overall Participants	45	45	90
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	35.7 (10.5)	34.8 (9.5)	35.0 (10.0)
Sex: Female, Male (Count of Participants)
Female	28 62.2%	30 66.7%	58 64.4%
Male	17 37.8%	15 33.3%	32 35.6%
Region of Enrollment (participants) [Number]
United States	45 100%	45 100%	90 100%
Numeric Rating Scale of Pain score (score) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [score]	8.49 (1.5)	8.64 (1.5)	8.57 (1.5)

Outcome Measures

1. Primary Outcome

Title	Numeric Rating Scale of Pain
Description	We will compare efficacy as a difference between 2 groups in pain score at 30 minutes post-analgesic administration. The primary outcome is the difference between 2 groups in pain score at 30 minutes. Pain will be measured via Numeric rating scale from 0 to 10 with 0 being no pain, 5 being moderate pain, and 10 being severe pain
Time Frame	30 minutes

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Morphine	Ketamine Group
Arm/Group Description	Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP Morphine: Morphine: 0.1 mg /kg given as IVP	Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP Ketamine: Ketamine:0.3 mg/given as IVP
Measure Participants	45	45
Mean (Standard Deviation) [Units on a scale]	3.93 (3.1)	4.07 (3.2)

Adverse Events

Time Frame	Within 2 hours of administration of either morphine or ketamine
Arm/Group Title	Morphine		Ketamine Group
Arm/Group Description	Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP Morphine: Morphine: 0.1 mg /kg given as IVP		Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP Ketamine: Ketamine:0.3 mg/given as IVP
All Cause Mortality
	Morphine		Ketamine Group
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Morphine		Ketamine Group
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/45 (0%)		0/45 (0%)
Other (Not Including Serious) Adverse Events
	Morphine		Ketamine Group
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	15/45 (33.3%)		14/45 (31.1%)
Gastrointestinal disorders
Nausea	9/45 (20%)	9	6/45 (13.3%)	6
General disorders
Dizziness	6/45 (13.3%)	6	8/45 (17.8%)	8

Limitations/Caveats

This was a single center study in which patients were enrolled as a convenience. There was the potential for unblinding as some participants exhibited ketamine specific reactions such as nystagmus.

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.